118 related articles for article (PubMed ID: 31298597)
1. Effect of imatinib on growth in children with chronic myeloid leukemia.
Boddu D; Thankamony P; Guruprasad CS; Nair M; Rajeswari B; Seetharam S
Pediatr Hematol Oncol; 2019 May; 36(4):189-197. PubMed ID: 31298597
[TBL] [Abstract][Full Text] [Related]
2. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.
Millot F; Guilhot J; Baruchel A; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Nicolas Sirvent ; Yacouben K; Chastagner P; Gandemer V; Reguerre Y; Couillault G; Khalifeh T; Rialland F
Eur J Cancer; 2014 Dec; 50(18):3206-11. PubMed ID: 25459396
[TBL] [Abstract][Full Text] [Related]
3. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.
Shima H; Tokuyama M; Tanizawa A; Tono C; Hamamoto K; Muramatsu H; Watanabe A; Hotta N; Ito M; Kurosawa H; Kato K; Tsurusawa M; Horibe K; Shimada H
J Pediatr; 2011 Oct; 159(4):676-81. PubMed ID: 21592517
[TBL] [Abstract][Full Text] [Related]
4. Imatinib has adverse effect on growth in children with chronic myeloid leukemia.
Bansal D; Shava U; Varma N; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2012 Sep; 59(3):481-4. PubMed ID: 22052850
[TBL] [Abstract][Full Text] [Related]
5. [Effect of imatinib on the height of children with chronic myeloid leukemia in the chronic phase].
Zheng FY; Zhang Y; Zhang LQ; Liu BC; Meng L; Jin J; Liu HL; Sun ZM; Lin LE; Lei PC; Zhu XF; Ma HX; Lu ZS; Jiang H; Zhao YH; Lin H; Zhang X; Yang GP; Zhu HL; Chen SN; You Y; Li WM; Bai QX; Zhao XL; Li ZY; Shen XM; Zhang LP; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):545-551. PubMed ID: 32810960
[No Abstract] [Full Text] [Related]
6. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
Rastogi MV; Stork L; Druker B; Blasdel C; Nguyen T; Boston BA
Pediatr Blood Cancer; 2012 Nov; 59(5):840-5. PubMed ID: 22378641
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of imatinib in children with chronic myelogenous leukemia.
Choeyprasert W; Yansomdet T; Natesirinilkul R; Wejaphikul K; Charoenkwan P
Pediatr Int; 2017 Mar; 59(3):286-292. PubMed ID: 27541072
[TBL] [Abstract][Full Text] [Related]
8. Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia.
Zheng FY; Lu AD; Zuo YX; Jia YP; Wu J; Zhang LP
Leuk Res; 2020 Aug; 95():106405. PubMed ID: 32590107
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia.
Jeyaraman P; Naithani R
J Pediatr Hematol Oncol; 2020 Jan; 42(1):e64-e65. PubMed ID: 31688623
[TBL] [Abstract][Full Text] [Related]
10. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.
Narayanan KR; Bansal D; Walia R; Sachdeva N; Bhansali A; Varma N; Marwaha RK
Pediatr Blood Cancer; 2013 Jul; 60(7):1148-53. PubMed ID: 23322583
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
12. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
[TBL] [Abstract][Full Text] [Related]
13. Imatinib-Induced Hypogammaglobulinemia in Children and Adolescents with Chronic Myeloid Leukemia.
Totadri S; Thipparapu S; Aggarwal R; Sharma M; Naseem S; Jain R; Trehan A; Malhotra P; Varma N; Bansal D
Pediatr Hematol Oncol; 2020 Sep; 37(6):539-544. PubMed ID: 32364815
[TBL] [Abstract][Full Text] [Related]
14. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
15. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
[TBL] [Abstract][Full Text] [Related]
16. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
17. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
[TBL] [Abstract][Full Text] [Related]
18. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
19. Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.
Giona F; Saglio G; Santopietro M; Menna G; Putti MC; Micalizzi C; Iaria G; Santoro N; Ladogana S; Mura R; Burnelli R; Consarino C; Cosmi C; Moleti ML; Leszl A; Tucci F; Nanni M; Diverio D; Biondi A; Locatelli F; Foà R
Br J Haematol; 2018 Mar; 180(6):895-898. PubMed ID: 27984633
[No Abstract] [Full Text] [Related]
20. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
